REG - GENinCode PLC - Result of General Meeting, Issue of Equity and TVR

GenincodeAnnouncement

03/03/2025 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250303:nRSC1292Za&default-theme=true

RNS Number : 1292Z  GENinCode PLC  03 March 2025

3 March 2025

 

 

 

GENinCode Plc

("GENinCode" or the "Company")

 

Result of General Meeting, Issue of Equity and Total Voting Rights

 

GENinCode plc (AIM: GENI), the genetics company focused on the prevention of
cardiovascular disease ("CVD") and the early detection of ovarian cancer,
announces that all resolutions put to Shareholders at the General Meeting held
earlier today in connection with the placing, subscription and retail offer
announced by the Company on 14 February 2025 were duly passed.

 

 

 Resolution                                                                            For                    Against                Withheld         Total votes cast
                                                                                       Number of votes  %     Number of votes  %     Number of votes
 1       Ordinary resolution to authorise the directors to allot shares                101,870,872      100%  -                0%    7                101,870,879
 2       Special resolution to authorise the directors to disapply pre-emption rights  101,866,990      100%  -                0%    3,889            101,870,879

(1)     Any proxy appointments, which gave discretion to the Chairman have
been included in the 'For' votes total.

(2)     Votes "For" and "Against" any resolution are expressed as a
percentage of votes validly cast for that resolution.

(3)     A vote "Withheld" is not a vote in law and is not counted in the
calculation of the percentage of shares voted "For" or "Against", nor in the
aggregate figure of total votes cast.

 

 

Subscription by the Nestor Oller entities

 

The Company has been notified by Nestor Oller, a significant shareholder in
the Company, of a change in the legal entity subscribing for 9,459,460 shares,
transferring from Bobby Jean SICAV S.A. to Santi-1990 SL. Both entities are
undertakings controlled by Nestor Oller.

 

Issue of Equity and Total Voting Rights

 

Following shareholder approval at the general meeting and conditional on
admission, 88,040,541 new ordinary shares have been allotted pursuant to the
Placing, 1,809,508 new ordinary shares pursuant to the Retail Offer and
20,067,567 pursuant to the Subscription.

 

The Company has therefore allotted a total of 109,917,616 new ordinary shares
in connection with the Fundraising.

 

Admission is expected to take place at 8.00 a.m. on or around 4 March 2025.

 

Following Admission, the total number of Ordinary Shares in the capital of the
Company in issue will be 286,882,042 with each Ordinary Share carrying the
right to one vote. There are no shares held in treasury and therefore,
following Admission, the total number of voting rights in the Company will be
286,882,042.

 

The above figure may be used by Shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure, Guidance and Transparency Rules.

 

Capitalised terms used in this announcement have the meaning given to them in
the announcement of the Placing and Subscription dated 14 February 2025,
unless otherwise defined in this announcement.

 

 

 

Enquiries:

 

 GENinCode Plc

 Matthew Walls, CEO                                                       www.genincode.com (http://www.genincode.com/)  or via Walbrook PR

 Paul Foulger, CFO

 Cavendish Capital Markets Limited (Nomad, Broker and Joint Bookrunner)   Tel: +44 (0)20 7397 8900
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks (Life Sciences Specialist Sales)

 Ondraya Swanson (Corporate Broking)

 Dale Bellis / Michael Johnson (Sales)

 Oberon Capital (Joint Bookrunner)                                        Tel: +44 (0) 203 179 5300

 Mike Seabrook / Aimee McCusker (Corporate Broking)                       corporatesales@oberoninvestments.com

 Nick Lovering / Jessica Cave (Corporate Finance)

 Walbrook PR Limited                                                      Tel: 020 7933 8780 or
 Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage                       genincode@walbrookpr.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMSSEFEDEISEID